RxDoctor Payments Data

Daniel Kessel, MD

Dermatology · Hamilton Square, NJNPI 1063449700

Payments from drug & device makers

$605in general payments, 2019–2025

Across 22 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$218
  • AbbVie$102
  • Strata Skin Sciences, Inc.$95
  • Johnson & Johnson$72
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$58
  • Pfizer$28
  • plus $33 from 4 others

What the payments were for

  • Food & beverage$53388%
  • Education$7212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sun Pharmaceutical Industries Inc.3$218
AbbVie5$102
Strata Skin Sciences, Inc.1$95
Johnson & Johnson1$72
Ortho Dermatologics, A Division Of Bausch Health US, LLC4$58
Pfizer2$28
Merck1$15
Mayne Pharma Commercial LLC1$13
Organon1$4
Medimetriks Pharmaceuticals, Inc.3$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$605 in reported general payments places this provider in the 25th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$239,399
Medicare patients
864
Services billed
3,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole13$15,104
Tacrolimus51$7,008
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc89$3,772
Calcipotriene17$2,833
Fluorouracil50$2,639
Ketoconazole117$2,330
Clindamycin Phosphate60$1,547
Clobetasol Propionate33$1,198
Fluocinonide48$1,160
Mometasone Furoate82$1,090
CiclopiroxCiclopirox Olamine60$1,088
Imiquimod22$961
Gentamicin Sulfate31$947
Triamcinolone Acetonide149$927
Azelaic Acid13$826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$58$15,10413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Hamilton Square

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →